Find Nonprofit and Small Business Grants

Saskatchewan.GrantWatch.com

Advance Search

Only Available for Paid Subscribers
Clear Filters
GrantWatch.com
Search Filters

Grants and In-Kind Support to USA, Canada, and UK Researchers to Encourage the Development of Drugs to Prevent, Treat, and Reverse Alzheimer's Disease

ADDF-Harrington Scholar Program


Grant Writers
Agency
Foundation
GrantWatch ID#
182103
Funding Source
ALZHEIMERS DRUG DISCOVERY FOUNDATION
and Harrington Discovery Institute
Array ( [0] => American Samoa (USA); [1] => Guam (USA); [2] => Puerto Rico (USA); [3] => Virgin Islands (USA); [4] => Northern Mariana Islands (USA); )
Geographic Focus
All USA
USA Territories: American Samoa (USA);   Guam (USA);   Puerto Rico (USA);   Virgin Islands (USA);   Northern Mariana Islands (USA);
Canada: Alberta;   British Columbia;   Manitoba;   New Brunswick;   Newfoundland and Labrador;   Northwest Territories;   Nova Scotia;   Nunavut;   Ontario;   Prince Edward Island;   Quebec;   Saskatchewan;   Yukon;
International
Important Dates
LOI Date: 06/02/25
Deadline: 08/18/25 5:00 PM EDT Save
Grant Description
Grants and in-kind assistance and advice to USA, Canada, and UK faculty members at IHEs or research centers to promote the development of drugs to prevent, treat, reverse, or slow the development of Alzheimer's disease and related dementias. Applicants must submit a letter of intent, and new applicants must register in the grant portal prior to applying. The program places high priority on targets related to emerging therapeutic areas for dementia and is particularly seeking projects related to proteostasis and senescence.

The ADDF-Harrington Scholar Program is dedicated to advancing academic discoveries into medicines for Alzheimer’s disease and related dementias. This unique award provides funding and project support by a team of pharmaceutical industry experts through a collaboration with the Alzheimer’s Drug Discovery Foundation (ADDF) and the Brain Health Medicines Centers of the Harrington Discovery Institute.

Funding Priorities:

Drug Targets

The 2026 ADDF-Harrington Scholar RFP places high priority on targets related to emerging therapeutic areas for dementia, particularly:

  • Proteostasis (including autophagy, lysosomal biogenesis, proteasomal degradation, post-translational modification associated with proteostasis, protein folding/misfolding, ER stress, and extracellular clearance)
  • Senescence (including cells that have halted division, shifted towards a secretory phenotype, altered morphology and epigenetics, and decreased apoptosis)
Other novel targets are encouraged. These include, but are not limited to:
  • Epigenetics
  • Vascular pathology
  • Neuroprotection
  • Synaptic activity and neurotransmitters
  • Inflammation
  • Mitochondrial health
  • Antioxidant defense
  • Metabolic function and brain energy
  • Brain insulin resistance
  • ApoE
  • Glymphatic clearance
  • Postnatal neurogenesis
  • Other aging targets

For additional information about Funding Priorities and Expectations, see the Full Grant Text RFP link.
Full Grant Text RFP
Recipient
Additional Eligibility Criteria
Eligibility Criteria:
• Academic investigators at accredited medical centers, research institutions, and universities in the United States, Canada and United Kingdom only are eligible to apply.
• Lead investigator must have an MD, a PhD, or equivalent.
• Proposals should show potential to advance discovery into meaningful therapeutics to treat, prevent, slow, or reverse Alzheimer’s disease or related dementias (vascular dementia, frontotemporal dementia, Lewy Body dementia, LATE etc).
• Team should possess intellectual property (IP) or have potential for novel IP that has not yet been licensed to a for-profit entity.
• Researchers working on drug development programs that are relevant to but not presently focused on the Alzheimer’s field are strongly encouraged to apply.
Ineligible
The ADDF-Harrington Scholar Program does not support anti-amyloid approaches (e.g. Abeta vaccines, beta- or gamma-secretase inhibitors) or cholinesterase inhibitors. Approaches targeting tau will be considered if distinction from those already in clinical development is clearly demonstrated.

This RFP does not support target discovery, assay development or high throughput screening campaigns.

Unallowable Costs:
ADDF funding is not provided for indirect costs/overhead, capital equipment, equipment service contracts, publication costs, or travel (unless travel is pre-approved under special circumstances).
Pre-Application Information
Timeline:
• Letter of Intent: June 2, 2025, 5:00 PM EDT
• Full Proposal: August 18, 2025, 5:00 PM EDT
• Award decisions are anticipated by March 2026.

Applicants are required to create an account using the ADDF Funding Portal to begin the application process. Please note, new applicants should allow 1-2 business days for registration.

The awards are provided as milestone-driven payments. Progress will be reviewed regularly by an oversight committee.

Applications and award budgets should be built around milestones. Milestones are key points in a project that represent reliable, quantifiable indicators/deliverables of progress and are used to make decisions on further funding.

Applicants may only submit one LOI per cycle and one invited full proposal per cycle, but a single academic institution may have multiple applicants apply for funding for different projects within a cycle. Biotechnology companies are limited to the submission of one LOI and one invited full proposal per cycle.

For Therapeutics RFPs, applicants are invited to resubmit proposals up to two times if they are able to address the reviewers' concerns. Resubmissions should include a point-by-point response to the review critiques.

Application Instructions: https://www.alzdiscovery.org/research-and-grants/funding-opportunities/harrington-application-instructions

Application and Funding Policies: https://www.alzdiscovery.org/research-and-grants/funding-opportunities/policies
Estimated Size of Grant
The award typically entails up to $600,000 over 2 years with dedicated support for milestone-driven projects from a team of industry veterans with capabilities that include medicinal chemistry, pharmacology and toxicology, and business development. The expertise of each team is tailored to the specific needs of the project during the two-year award period.
Term of Contract
The funding period is for two years.
Contact Information
Online application portal: https://addf.fluxx.io/user_sessions/new

For scientific inquiries, please contact:
Harrington Discovery Institute
Andrew A. Pieper, MD, PhD
Director, Center for Brain Health Medicines
Harrington Discovery Institute
Andrew.Pieper@harringtondiscovery.org
Website: www.harringtondiscovery.org/addf

Alzheimer’s Drug Discovery Foundation
Meriel Owen, PhD
Associate Director, Search and Evaluation
mowen@alzdiscovery.org

For application submission inquiries, please contact:
Grants and Contracts Team
grants@alzdiscovery.org

57 West 57th Street, Suite 904
New York, NY 10019
info@alzdiscovery.org
212.901.8000
Categories

We have foundations for

We have grants for

Grant News
Live Chat Chat Now